Exposure to valproate (trade names of the preparation include Depakine, Orfiril and Convulex) during pregnancy can result in congenital anomalies and developmental disorders following birth. Women with epilepsy who wish to have children should therefore consult their doctor in good time so that their medication can be adjusted.
Patient information brochure – valproate
Guidelines for medical professionals – valproate
Form for annual confirmation that risks have been explained – treatment of female patients with valproate
Patient card – valproate